INTRODUCTION
============

The World Health Organization guidelines \[[@b1-kjim-2017-063]\] and the Response Evaluation Criteria in Solid Tumors (RECIST) \[[@b2-kjim-2017-063],[@b3-kjim-2017-063]\] are the morphologic criteria commonly used to assess tumor response in clinical practice. However, these criteria depending on the size changes based on computed tomography (CT) have limitations in tumors with obscure margins, cystic lesion, or scar tissue. In particular, measuring the longest diameter of lesions on CT is not always possible in gastrointestinal tumors. Because patients treated with targeted agents were not included in the data warehouse \[[@b4-kjim-2017-063]\] when the RECIST version 1.1 was revised \[[@b3-kjim-2017-063]\], there has also been concern regarding the assessment of tumor responses with the RECIST in patients receiving targeted agents \[[@b5-kjim-2017-063]\]. Molecular targeted agents tend to induce necrotic or cystic change, not tumor shrinkage, in solid tumors \[[@b6-kjim-2017-063]\]. Therefore, morphologic response criteria may be not well suited for assessing the efficacy of targeted therapies that stabilize diseases.

\[18F\]-fluorodeoxyglucose (\[18F\]-FDG) uptake is enhanced in most malignant tumors which in turn can be measured by positron emission tomography (PET). \[18F\]-FDG PET has been adopted as a new method for the diagnosis and staging of solid tumors. PET is also increasingly being used to monitor tumor responses to anti-cancer therapies. It can allow the assessment of tumor response even in the absence of anatomical changes \[[@b7-kjim-2017-063]-[@b9-kjim-2017-063]\]. There are two sets of criteria using FDG PET to quantify metabolic changes to anti-cancer treatment: the criteria developed by the European Organization for Research and Treatment of Cancer (EORTC) criteria \[[@b10-kjim-2017-063]\] and the Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) \[[@b11-kjim-2017-063]\]. Tumor response evaluations with the PERCIST and EORTC criteria have shown almost perfect agreement and correlated well with survival \[[@b12-kjim-2017-063],[@b13-kjim-2017-063]\]. The metabolic response criteria may provide clinicians with a more accurate assessment of therapeutic response at an earlier stage of treatment course. However, their usefulness and advantage over the morphologic criteria (RECIST) need to be further investigated.

The assessment of tumor responses between the morphologic criteria and metabolic criteria has shown considerable discrepancies in a series of studies with a small number of patients \[[@b14-kjim-2017-063]-[@b27-kjim-2017-063]\]. We performed this pooled study to compare tumor response assessment between the morphologic criteria (RECIST 1.0 and RECIST 1.1) and metabolic criteria (EORTC criteria and PERCIST) in patients with solid tumors.

METHODS
=======

Search strategy
---------------

A computerized systematic search of the electronic databases PubMed, Embase, Scopus, and Google Scholar (up to June 2017) was carried out to find articles with the following terms in their titles, abstracts, or keywords: "RECIST," "PERCIST," or "'EORTC criteria." In addition, we checked all the references of identified relevant articles and reviews. We also used the "related articles" feature in PubMed to identify relevant articles.

Study selection criteria
------------------------

Studies comparing tumor responses by using the RECIST and metabolic criteria (EORTC or PERCIST) were considered for inclusion in this pooled study. As the RECIST 1.1 showed a high concordance with the RECIST 1.0 in the assessment of tumor responses \[[@b28-kjim-2017-063],[@b29-kjim-2017-063]\], we included both versions without distinction in the analysis. For a more accurate comparison, however, articles adopting the modified RECIST versions developed for specific types of tumors were excluded. The searched articles were screened again by reviewing the full text, and the original articles that compared tumor responses between the morphologic criteria (RECIST 1.0 or RECIST 1.1) and metabolic criteria (PERCIST or EORTC) were included in the final analysis.

Tumor response assessment
-------------------------

The tumor responses according to the RECIST in each study were defined as follows \[[@b2-kjim-2017-063],[@b3-kjim-2017-063]\]: (1) complete response (CR): disappearance of all lesions; (2) partial response (PR): at least a 30% decrease in the sum of diameters of the target lesions and no new lesions; (3) progressive disease (PD): more than a 20% increase in the sum of diameters of the target lesions (and also an absolute increase of at least 5 mm in the RECIST 1.1) or the appearance of new lesions on CT (or PET in the RECIST 1.1); and (4) stable disease (SD): neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD.

The tumor response guidelines for the PERCIST and EORTC criteria are briefly summarized in [Table 1](#t1-kjim-2017-063){ref-type="table"}.

Statistics
----------

The overall response rate (ORR) was defined as the percentage of patients with CR or PR (as determined by the two RECIST versions) and those with complete metabolic response (CMR) or partial metabolic response (PMR) (as determined by the PERCIST or EORTC criteria). The ORRs between the two groups were compared by using the McNemar test and *p* values less than 0.05 were considered significant. The level of agreement in tumor responses between the two criteria was estimated using unweighted κ statistics. The agreement was interpreted as poor (κ \< 0), slight (κ = 0 to 0.20), fair (κ = 0.21 to 0.40), moderate (κ = 0.41 to 0.60), substantial (κ = 0.61 to 0.80), and almost perfect (κ \> 0.80) \[[@b30-kjim-2017-063]\].

Ethics
------

This study did not require approval by an ethics committee because it was a pooled analysis with systematic review of previously published studies. We performed this study according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines \[[@b31-kjim-2017-063]\].

RESULTS
=======

Eligible studies
----------------

[Fig. 1](#f1-kjim-2017-063){ref-type="fig"} shows the flowchart of studies. A total of 132 studies were identified according to the search strategy: 110 were excluded after screening the titles and abstracts. The remaining 22 articles comparing tumor responses according to the RECIST and metabolic criteria were potentially relevant. However, eight studies were excluded based on the inclusion criteria: three articles used the modified RECIST and five had no details of response classification \[[@b32-kjim-2017-063]-[@b36-kjim-2017-063]\].

Finally, 14 studies with data comparing tumor responses by the RECIST and morphologic criteria (EORTC or PERCIST) were selected \[[@b14-kjim-2017-063]-[@b27-kjim-2017-063]\]. Five articles compared the RECIST and EORTC criteria \[[@b14-kjim-2017-063],[@b16-kjim-2017-063]-[@b19-kjim-2017-063]\] and six compared the RECIST and PERCIST \[[@b22-kjim-2017-063]-[@b27-kjim-2017-063]\]. The remaining three studies compared the RECIST and both metabolic criteria \[[@b15-kjim-2017-063],[@b20-kjim-2017-063],[@b21-kjim-2017-063]\].

Patients' characteristics
-------------------------

From the eight studies comparing the RECIST and EORTC criteria \[[@b14-kjim-2017-063]-[@b21-kjim-2017-063]\], 216 patients were included; 82 with lung cancer \[[@b19-kjim-2017-063]-[@b21-kjim-2017-063]\], 45 with colorectal cancer \[[@b14-kjim-2017-063],[@b20-kjim-2017-063]\], 33 with head and neck cancer \[[@b18-kjim-2017-063],[@b20-kjim-2017-063]\], 17 with malignant melanoma \[[@b17-kjim-2017-063]\], 14 with basal cell carcinoma \[[@b15-kjim-2017-063]\], 12 with stomach cancer \[[@b20-kjim-2017-063]\], seven with desmoplastic small round cell tumors \[[@b16-kjim-2017-063]\], and six with breast cancer \[[@b20-kjim-2017-063]\] ([Table 2](#t2-kjim-2017-063){ref-type="table"}). Eighty-nine patients (41.2%) were treated with targeted agents and 127 (58.8%) received cytotoxic chemotherapy.

From the nine studies comparing tumor responses by the RECIST and PERCIST, 407 patients were included \[[@b15-kjim-2017-063],[@b20-kjim-2017-063]-[@b27-kjim-2017-063]\]: 120 with colorectal cancer \[[@b20-kjim-2017-063],[@b23-kjim-2017-063],[@b27-kjim-2017-063]\], 95 with lung cancer \[[@b20-kjim-2017-063]-[@b22-kjim-2017-063]\], 93 with breast cancer \[[@b20-kjim-2017-063],[@b25-kjim-2017-063],[@b26-kjim-2017-063]\], 48 with esophageal cancer \[[@b24-kjim-2017-063],[@b25-kjim-2017-063]\], 14 with basal cell carcinoma \[[@b15-kjim-2017-063]\], 12 with stomach cancer \[[@b20-kjim-2017-063]\], 10 with head and neck cancer \[[@b20-kjim-2017-063],[@b25-kjim-2017-063]\], and 16 with other cancers ([Table 3](#t3-kjim-2017-063){ref-type="table"}) \[[@b25-kjim-2017-063]\].

Comparison of tumor responses between the RECIST and EORTC criteria
-------------------------------------------------------------------

Because the RECIST 1.1 includes PET scans for the detection of new lesions, we reclassified tumor response of two patients with new focal FDG avid marrow lesions as PD \[[@b19-kjim-2017-063]\]. The rate of discordance in tumor responses between the RECIST (RECIST 1.0 and RECIST 1.1) and EORTC criteria varied from 9.7% in non-small cell lung cancer \[[@b19-kjim-2017-063]\] to 80% in colorectal cancer \[[@b14-kjim-2017-063]\] ([Table 2](#t2-kjim-2017-063){ref-type="table"}). The agreement of tumor response between the two criteria was moderate (κ = 0.447; 95% confidence interval, 0.356 to 0.537) ([Table 4](#t4-kjim-2017-063){ref-type="table"}). Of 216 patients, 86 (39.8%) showed discordance in the assessment of their tumor responses between the two criteria. The details of the patients showing disagreement are described in [Table 2](#t2-kjim-2017-063){ref-type="table"}. When adopting the EORTC criteria, tumor responses were upgraded in 70 patients and downgraded in 16. The shift in tumor responses occurred most frequently in patients with SD as determined by the RECIST. Among 68 patients with SD, the tumor response in 56 patients (82.46%) was upgraded to CMR (n = 3) or PMR (n = 53) and that in 12 was downgraded to progressive metabolic disease (PMD) by using the EORTC criteria. Of 10 patients with PR, six were reclassified as showing CMR, three as having stable metabolic disease (SMD), and one as having PMD. There were eight patients with PD who were upgraded as having PMR (n = 1) or SMD (n = 7). As a result, the estimated ORRs, which were estimated in total regardless of the primary tumor sites, were significantly different between the two criteria (28.2% by the RECIST vs. 52.8% by the EORTC, *p* \< 0.0001).

Comparison of tumor responses between the RECIST and PERCIST
------------------------------------------------------------

The rate of disagreement in tumor responses between the RECIST and PERCIST varied from 18.3% \[[@b20-kjim-2017-063]\] to 62.9% \[[@b25-kjim-2017-063]\]. Of 407 patients, 181 (44.5%) showed discordance in the assessment of their tumor responses between the two criteria. The details of the patients showing discordance are summarized in [Table 3](#t3-kjim-2017-063){ref-type="table"}. The agreement of tumor response between the two criteria was fair (κ = 0.398; 95% confidence interval, 0.323 to 0.456) ([Table 5](#t5-kjim-2017-063){ref-type="table"}). When adopting the PERCIST, the tumor response was upgraded in 151 patients and downgraded in 30. The shift in tumor responses was also observed most frequently in patients with SD by using the RECIST. Among 120 patients with SD, the tumor response of 96 patients (80%) was upgraded to CMR (n = 11) or PMR (n = 85) and that of 24 was downgraded to PMD by adopting the PERCIST. Of 37 patients with PR, 31 were reclassified as showing CMR and six as having SMD. There were 24 patients with PD who were upgraded as showing CMR (n = 4), PMR (n = 7), and SMD (n = 13). The estimated ORRs were also significantly different between the two criteria (30.2% by the RECIST vs. 55.0% by the PERCIST, *p* \< 0.0001).

DISCUSSION
==========

In this pooled study, we investigated the concordance between the metabolic criteria and morphologic criteria for the assessment of tumor responses in patients with solid tumors. There was a considerable discrepancy in the assessment of tumor responses between the morphologic criteria (RECIST) and metabolic criteria (EORTC or PERCIST). When adopting the EORTC criteria or PERCIST instead of the RECIST, the ORR was significantly increased, suggesting significant clinical impact of the metabolic criteria on making therapeutic decision.

In clinical practice, it is not always easy to distinguish necrotic tissue or fibrotic scar from residual tumor on CT scans \[[@b37-kjim-2017-063]\]. In particular, with the increasing use of targeted agents, new evaluation methods are needed to accurately monitor tumor responses. \[18F\]-FDG PET has become a well-established method for the staging and detection of recurrence in patients with several malignancies \[[@b38-kjim-2017-063]\]. It is also increasingly used to assess tumor responses to anti-cancer therapies \[[@b8-kjim-2017-063]-[@b10-kjim-2017-063]\]. FDG PET responses have correlated more significantly with survival than those assessed by CT \[[@b39-kjim-2017-063]\]. However, the metabolic response criteria have shown differences compared with the morphologic criteria for the assessment of tumor responses.

In our pooled analysis of 216 patients from eight studies \[[@b14-kjim-2017-063]-[@b21-kjim-2017-063]\], the agreement of tumor responses between the RECIST and EORTC criteria was moderate (κ = 0.447). Eighty-six patients (39.8%) showed discrepancies in the assessment of tumor responses between the two criteria. Use of the EORTC criteria resulted in upgraded tumor responses in 70 patients and downgraded responses in 16. When adopting the EORTC criteria, the ORR significantly increased from 28.2% to 52.8% (*p* \< 0.0001). The agreement of tumor responses between the RECIST and PERCIST was deemed fair (κ = 0.389). Of 407 patients from nine studies \[[@b15-kjim-2017-063],[@b20-kjim-2017-063]-[@b27-kjim-2017-063]\], 181 (44.5%) showed a disagreement in tumor responses between the two criteria. Use of the PERCIST resulted in upgraded tumor responses in 151 patients and downgraded responses in 30. When adopting the PERCIST instead of the RECIST, the ORR also significantly increased from 30.2% to 55.0% (*p* \< 0.0001).

Early detection of the tumor response is of great value to avoid unnecessary toxicity and cost of ineffective treatments. Anatomical responses based on the size of the tumor may lag weeks or months behind metabolic response \[[@b40-kjim-2017-063]\]. PET can detect metabolic changes after chemotherapy even when there are no or minimal morphological changes \[[@b7-kjim-2017-063]\], which may explain the reason why tumor responses were upgraded by using the metabolic criteria in many patients who showed SD by using the RECIST in this study. In clinical practice, patients showing disease progression (PD or PMD) after anti-cancer treatment usually need a change in therapeutic approach. If the metabolic criteria had been used instead of the RECIST in this pooled study, it would have changed the treatment course in approximately 10% of the patients. This finding indicates that the clinical impact of the metabolic response criteria on making therapeutic decisions is significant.

The current pooled study has several inherent limitations. First, this study included heterogeneous patients with different types of tumors and different kinds of therapeutic agents. In addition, because of the limited number of studies, we could not compare two criteria in the subgroup with the same cancers. It is necessary to verify these results in studies with larger homogeneous patients' cohort. Second, we included two versions of the RECIST without distinction in the analysis. Although the RECIST 1.1 has shown almost perfect agreement with the RECIST 1.0 in the assessment of tumor responses, a potential difference between the two versions might affect the results. Finally, this study could not evaluate the prognostic value of the metabolic criteria. Although the PERCIST and EORTC criteria were associated with prognosis in several studies, survival data were not enough to compare the prognostic value between the RECIST and the metabolic criteria.

In conclusion, this pooled study demonstrates that concordance in the assessment of tumor responses between the morphologic criteria (RECIST) and metabolic criteria (EORTC or PERCIST) is not excellent. When adopting the metabolic criteria instead of the RECIST, the ORR was significantly increased. The prognostic value of the metabolic criteria needs to be investigated in larger studies with homogeneous patient cohorts.

KEY MESSAGE
===========

1\. The assessment of tumor responses between the morphologic criteria and metabolic criteria has shown considerable discrepancies in studies with a small sample size.

2\. The agreement of tumor responses was moderate between the morphologic (Response Evaluation Criteria in Solid Tumors \[RECIST\]) and metabolic criteria (European Organization for Research and Treatment of Cancer or Positron Emission Tomography Response Criteria in Solid Tumors).

3\. When adopting the metabolic criteria instead of the RECIST, the overall response rate was significantly increased.
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![Flowchart of search process. RECIST, Response Evaluation Criteria in Solid Tumors; EORTC, European Organization Research and Treatment of Cancer; PERCIST, Positron Emission Tomography Response Criteria in Solid Tumors.](kjim-2017-063f1){#f1-kjim-2017-063}

###### 

Tumor response assessment by two metabolic criteria (EORTC criteria and PERCIST)

                                        EORTC                                                                         PERCIST
  ------------------------------------- ----------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------
  Complete metabolic response (CMR)     Complete resolution of FDG uptake in all lesions                              Complete resolution of FDG uptake in all lesions
  Partial metabolic response (PMR)      ≥ 25% Reduction in the sum of SUVmax after more than one cycle of treatment   ≥ 30% Reduction of the SULpeak and an absolute drop of 0.8 SULpeak units
  Progressive metabolic disease (PMD)   ≥ 25% Increase in the sum of SUVmax or appearance of new FDG-avid lesions     ≥ 30% Increase in the SULpeak of the FDG uptake and an absolute increase of 0.8 SULpeak, or appearance of FDG-avid new lesions
  Stable metabolic disease (SMD)        Not qualify for CMR, PMR, or PMD                                              Not qualify for CMR, PMR, or PMD

EORTC, European Organization Research and Treatment of Cancer; PERCIST, Positron Emission Tomography Response Criteria in Solid Tumors; FDG, fluorodeoxyglucose; SUVmax, maximum standardized uptake value; SULpeak, peak lean body mass SUV.

###### 

Summary of eight studies comparing the RECIST and EORTC criteria

  Study                                                                                           Tumor type                            No. of pts                    Treatment                      Comparison                 Discordant rate, %   Details of discordance
  ----------------------------------------------------------------------------------------------- ------------------------------------- ----------------------------- ------------------------------ -------------------------- -------------------- ---------------------------
  Monteil et al. (2009) \[[@b14-kjim-2017-063]\]                                                  Colorectal cancer                     25                            Palliative chemotherapy        RECIST 1.0 vs. EORTC       80 (20/25)           3 PR→2 CMR, 1 PMD
  17 SD→3 CMR, 13 PMR, 1 PMD                                                                                                                                                                                                                         
  Thacker et al. (2012) \[[@b15-kjim-2017-063]\]                                                  Basal cell carcinoma                  14                            Targeted agent (vismodegib)    RECIST 1.0 vs. PER- CIST   50 (7/14)            2 PR→1 CMR, 1 SMD
  4 SD→4 PMR                                                                                                                                                                                                                                         
  1 PD→1 SMD                                                                                                                                                                                                                                         
  Magnan et al. (2013) \[[@b16-kjim-2017-063]\]                                                   Desmoplastic small round cell tumor   7                             Chemotherapy                   RECIST 1.0 vs. EORTC       71.4 (5/7)           5 SD→5 PMR
  Adkin et al. (2014) \[[@b17-kjim-2017-063]\]                                                    Head & neck cancer                    27                            Targeted therapy (cetuximab)   RECIST 1.0 vs. EORTC       51.9 (14/27)         14 SD→9 PMR, 5 PMD
  Zukotynski et al. (2014) \[[@b18-kjim-2017-063]\]                                               Malignant melanoma                    17                            Targeted therapy (imatinib)    RECIST 1.0 vs. EORTC       29.4 (5/17)          1 PR→1 SMD
  1 SD→1 PMD                                                                                                                                                                                                                                         
  3 PD→1 PMR, 2 SMD                                                                                                                                                                                                                                  
  Puranik et al. (2015) \[[@b19-kjim-2017-063]\]^[a](#tfn1-kjim-2017-063){ref-type="table-fn"}^   Non-small cell lung cancer            31                            Targeted therapy (gefitinib)   RECIST 1.1 vs. EORTC       9.7 (3/31)           3 SD→3 PMR
  Aras et al. (2016) \[[@b20-kjim-2017-063]\]                                                     Colorectal cancer                     20                            Chemotherapy                   RECIST 1.1 vs. EORTC       20 (12/60)           4 PR→3 CMR, 1 SMD
  Lung cancer                                                                                     16                                    8 SD→7 PMR, 1 PMD                                                                                            
  Stomach cancer                                                                                  12                                                                                                                                                 
  Head & neck cancer                                                                              6                                                                                                                                                  
  Breast cancer                                                                                   6                                                                                                                                                  
  Shang et al. (2016) \[[@b21-kjim-2017-063]\]                                                    Non-small cell lung cancer            35                            Chemotherapy                   RECIST 1.1 vs. EORTC       57.1 (20/35)         16 SD→12 PMR, 4 PMD
  4 PD→4 SMD                                                                                                                                                                                                                                         
  Summary                                                                                         Lung cancer                           82                                                           RECIST vs. EORTC           39.8 (86/216)        10 PR→6 CMR, 3 SMD, 1 PMD
  Colorectal cancer                                                                               45                                    68 SD→3 CMR, 53 PMR, 12 PMD                                                                                  
  Head & neck cancer                                                                              33                                    8 PD→1 PMR, 7 SMD                                                                                            
  Malignant melanoma                                                                              17                                                                                                                                                 
  Basal cell carcinoma                                                                            14                                                                                                                                                 
  Stomach cancer                                                                                  12                                                                                                                                                 
                                                                                                  Breast cancer                         6                                                                                                            
                                                                                                  Desmoplastic small round cell tumor   7                                                                                                            

RECIST, Response Evaluation Criteria in Solid Tumors; EORTC, European Organization Research and Treatment of Cancer; pts, patients; PR, partial response; CMR, complete metabolic response; PMD, progressive metabolic disease; SD, stable disease; PMR, partial metabolic response; SMD, stable metabolic disease; PD, progressive disease.

Because the RECIST 1.1 includes positron emission tomography for the detection of new lesions, two patients with new focal fluorodeoxyglucose avid marrow lesions were reclassified as having PD.

###### 

Summary of nine studies comparing the RECIST and PERCIST

  Study                                                                                            Tumor type                   No. of pts                      Treatment                                          Comparison               Discordant rate, %   Details of discordance
  ------------------------------------------------------------------------------------------------ ---------------------------- ------------------------------- -------------------------------------------------- ------------------------ -------------------- --------------------------
  Thacker et al. (2012) \[[@b15-kjim-2017-063]\]                                                   Basal cell carcinoma         14                              Targeted agent (vismodegib)                        RECIST 1.0 vs. PERCIST   50 (7/14)            2 PR→1 CMR, 1 SMD
  4 SD→4 PMR                                                                                                                                                                                                                                                     
  1 PD→1 SMD                                                                                                                                                                                                                                                     
  Aras et al. (2016) \[[@b20-kjim-2017-063]\]                                                      Colorectal cancer            20                              Palliative chemotherapy                            RECIST 1.1 vs. PERCIST   18.3 (11/60)         4 PR→3 CMR, 1 SMD
  Lung cancer                                                                                      16                           7 SD→7 PMR                                                                                                                       
  Stomach cancer                                                                                   12                                                                                                                                                            
  Head & neck cancer                                                                               6                                                                                                                                                             
  Breast cancer                                                                                    6                                                                                                                                                             
  Shang et al. (2016) \[[@b21-kjim-2017-063]\]                                                     Non-small cell lung cancer   35                              Chemotherapy                                       RECIST 1.1 vs. PERCIST   62.9 (22/35)         18 SD→14 PMR, 4 PMD
  4 PD→4 SMD                                                                                                                                                                                                                                                     
  Ding et al. (2014) \[[@b22-kjim-2017-063]\]                                                      Non-small cell lung cancer   44                              Palliative chemotherapy                            RECIST 1.1 vs. PERCIST   34.1 (15/44)         6 PR→4 CMR, 2 SMD
  9 SD→1 CMR, 7 PMR, 1 PMD                                                                                                                                                                                                                                       
  Skougaard et al. (2014) \[[@b23-kjim-2017-063]\]                                                 Colorectal cancer            61                              Palliative chemotherapy                            RECIST 1.0 vs. PERCIST   54.1 (33/61)         1 PR→1 SMD
  24 SD→20 PMR, 4 PMD                                                                                                                                                                                                                                            
  8 PD→4 PMR, 4 SMD                                                                                                                                                                                                                                              
  Yanagawa et al. (2012) \[[@b24-kjim-2017-063]\]^[a](#tfn2-kjim-2017-063){ref-type="table-fn"}^   Esophageal cancer            46                              Neoadjuvant chemotherapy                           RECIST 1.1 vs. PERCIST   56.5 (26/46)         13 PR→13 CMR
  13 SD→3 CMR, 10 PMR                                                                                                                                                                                                                                            
  Agrawal et al. (2014) \[[@b25-kjim-2017-063]\]                                                   Breast cancer                22                              Metronomic palliative hemotherapy                  RECIST 1.1 vs. PERCIST   20.6 (9/43)          8 SD→1 CMR, 1 PMR, 6 PMD
  PNET                                                                                             5                            1 PD→1 CMR                                                                                                                       
  Head & neck cancer                                                                               4                                                                                                                                                             
  Sarcoma                                                                                          3                                                                                                                                                             
  NHL                                                                                              2                                                                                                                                                             
  Esophageal cancer                                                                                2                                                                                                                                                             
  Others                                                                                           5                                                                                                                                                             
  Riedl et al. (2017) \[[@b26-kjim-2017-063]\]                                                     Breast cancer                65                              Chemotherapy, targeted therapy, hormonal therapy   RECIST 1.1 vs. PERCIST   52.3 (34/65)         10 PR→10 CMR
  20 SD→6 CMR, 8 PMR, 6 PMD                                                                                                                                                                                                                                      
  4 PD→3 CMR, 1 SMD                                                                                                                                                                                                                                              
  Bang et al. (2017) \[[@b27-kjim-2017-063]\]                                                      Colorectal cancer            39                              Targeted therapy (regorafenib)                     RECIST 1.1 vs. PERCIST   61.5 (24/39)         1 PR→1 SMD
  17 SD→14 PMR, 3 PMD                                                                                                                                                                                                                                            
  6 PD→3 PMR, 3 SMD                                                                                                                                                                                                                                              
  Summary                                                                                          Colorectal cancer            120                                                                                RECIST vs. PERCIST       44.5 (181/407)       37 PR→31 CMR, 6 SMD
  Lung cancer                                                                                      95                           120 SD→11 CMR, 85 PMR, 24 PMD                                                                                                    
  Breast cancer                                                                                    93                           24 PD→4 CMR, 7 PMR, 13 SMD                                                                                                       
  Esophageal cancer                                                                                48                                                                                                                                                            
  Basal cell carcinoma                                                                             14                                                                                                                                                            
  Stomach cancer                                                                                   12                                                                                                                                                            
  Head & neck cancer                                                                               10                                                                                                                                                            
  Others                                                                                           16                                                                                                                                                            

RECIST, Response Evaluation Criteria in Solid Tumors; PERCIST, Positron Emission Tomography Response Criteria in Solid umors; pts, patients; PR, partial response; CMR, complete metabolic response; SMD, stable metabolic disease; SD, stable disease; PMR, partial metabolic response; PD, progressive disease; PMD, progressive metabolic disease; PNET, primitive neuroectodermal tumor; NHL, non-Hodgkin's lymphoma.

Five patients were excluded from the final analysis because their disease was not classifiable according to the RECIST 1.1.

###### 

Comparison of tumor responses according to the RECIST and EORTC criteria

  Tumor response by the RECIST   Tumor response by the EORTC   Total             
  ------------------------------ ----------------------------- ------- ---- ---- -----
  CR                             5                             0       0    0    5
  PR                             6                             46      3    1    56
  SD                             3                             53      25   12   93
  PD                             0                             1       7    54   62
  Total                          14                            100     35   67   216

The level of concordance of tumor responses between the EORTC criteria and RECIST is 0.447 (unweighted κ, 95% confidence interval, 0.356 to 0.537). The overall response rates were significantly different between the two criteria (28.2% by RECIST vs. 52.8% by EORTC, *p* \< 0.0001).

RECIST, Response Evaluation Criteria in Solid Tumors; EORTC, European Organization Research and Treatment of Cancer; CMR, complete metabolic response; PMR, partial metabolic response; SMD, stable metabolic disease; PMD, progressive metabolic disease; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.

###### 

Comparison of tumor responses according to the RECIST and PERCIST

  Tumor response by RECIST   Tumor response by PERCIST   Total              
  -------------------------- --------------------------- ------- ---- ----- -----
  CR                         8                           0       0    0     8
  PR                         31                          78      6    0     115
  SD                         11                          85      60   24    180
  PD                         4                           7       13   80    104
  Total                      54                          170     79   104   407

The level of concordance of tumor responses between the RECIST and PERCIST 1.0 is 0.389 (unweighted κ, with 95% confidence interval, 0.323 to 0.456). The overall response rates were significantly different between two criteria (30.2% by RECIST vs. 55.0% by PERCIST, *p* \< 0.0001).

RECIST, Response Evaluation Criteria in Solid Tumors; PERCIST, Positron Emission Tomography Response Criteria in Solid Tumors; CMR, complete metabolic response; PMR, partial metabolic response; SMD, stable metabolic disease; PMD, progressive metabolic disease; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
